RecruitingPhase 2NCT06097533

Improvement of Quality of Life by Cannabinoids in Oncologic Patients

Improvement of Quality of Life by Cannabinoids in Oncologic Patients (BEfindLichkeitsverbesserung Unter CANnabinoid-ExtrakTen Bei Onkologischen Patienten)

Sponsor

University Hospital Schleswig-Holstein

Enrollment

170 participants

Start Date

Apr 8, 2024

Study Type

INTERVENTIONAL

Conditions

Quality of Life Palliative Care Medical Oncology Cannabinoids

Summary

The goal is to explore whether the application of cannabis extract Avextra 10/10 solution is suitable to contribute to an improvement in the symptom burden and well-being of oncological palliative care patients. The primary objective of the study is to demonstrate the improvement in global symptom burden in the intervention arm compared to the placebo control group over a period of 12±2 days, as measured by a percentage change in the value of the Edmonton Symptom Assessment System total symptom distress score (ESAS TSDS) at baseline and after 12±2 days.

Eligibility

Min Age: 25 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cannabisextrakt Avextra 10/10 Lösung for people with cannabinoids, medical oncology, and other related conditions. The study is currently recruiting participants at 4 locations. People eligible for this study include aged 25 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.